![]() |
![]() |
| J Korean Med Assoc > Volume 69(9); 2026 > Article |
|
This table was made by the author based on the cited references.
SC, subcutaneous; CBC, complete blood count; LFT, liver function test; Cr, creatinine; HBV, hepatitis B virus; HCV, hepatitis C virus; q, every; OCT, optical coherence tomography; FAF, fundus autofluorescence; G6PD, glucose-6-phosphate dehydrogenase.
| Drug | JAK selectivity | Dosage |
|---|---|---|
| Tofacitinib | JAK1/3 | 5 mg bid, or 11 mg XR qd |
| Baricitinib | JAK1/2 | 2 mg or 4 mg qda) |
| Upadacitinib | JAK1 (selective) | 15 mg qd |
| Filgotinib | JAK1 (selective) | 100 mg or 200 mg qdb) |
The table was made by the author.
JAK, Janus kinase; bid, twice daily; XR, extended release; qd, once daily.
a)Baricitinib: 4 mg qd is the standard starting dose; may reduce to 2 mg qd once disease activity is sustainably controlled and dose tapering is appropriate. A starting dose of 2 mg qd is recommended in patients ≥65 years, with a history of chronic or recurrent infection, or at increased risk of venous thromboembolism, major adverse cardiovascular events, or malignancy; may escalate to 4 mg qd if disease activity is not adequately controlled. b)Filgotinib: 100 mg qd recommended as starting dose in patients ≥65 years, with moderate–severe renal impairment, or at increased risk of venous thromboembolism, major adverse cardiovascular events, and malignancy; may escalate to 200 mg qd if needed.
Current management of brain metastases: a narrative review2026 July;69(7)
Diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review2026 June;69(6)

![]() |
![]() |